Charles Roberts Named the Next President and CEO of St. Jude Children’s Research Hospital
oncodaily - Charles Roberts, Current Cancer Center Director and Executive Vice-President and Next President and CEO of St. Jude Children’s Research Hospital, shared St. Jude Children’s Research Hospital’s post on LinkedIn, adding: […]
AI Summary: Charles Roberts was named president and CEO of St. Jude Children’s Research Hospital, stepping into leadership of a globally recognized pediatric cancer and research institution. He’ll oversee strategy, fundraising and clinical priorities as the center pursues ambitious research and care goals — and deal with the inevitable complexity of running a world-class nonprofit hospital.
Essentia Health names EVP from SSM Health
Kelly Gooch / beckershospitalreview - Jason Craig, most recently a regional vice president at St. Louis-based SSM Health, was named executive vice president of administration and operations at Duluth, Minn.-based Essentia Health, according to an Aug. 12 news release shared with Becker’s. Mr. …
AI Summary: Recent analyses and expert commentary propose that genomic newborn screening can identify children with cancer predisposition syndromes before tumors develop. Early detection would enable targeted surveillance and preventive measures, though ethical, logistical, and equity considerations remain central to implementing such programs at scale. Expect lively debate before universal adoption.
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…
AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.
E. Anders Kolb: Blood Cancer United Preserves Access to Luveltamab Tazevibulin for Children with AML
oncodaily - E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared a post on LinkedIn: “Today we announced a first‑of‑its‑kind intervention from a nonprofit. Blood Cancer United has stepped up […]
AI Summary: A nonprofit stepped into a supply crisis and purchased the remaining stock of an experimental agent to preserve access for children with acute myeloid leukemia. The emergency buy protects current patients from treatment interruption while stakeholders scramble for a durable manufacturing or regulatory fix, illustrating how charities sometimes act like pharma’s safety net.
American Cancer Society Announces New Pediatric, Adolescent, and Young Adult Cancer Journal; Names Editor-in-Chief
cancer - The publication will provide a platform to share discoveries and advance knowledge across the field of pediatric and AYA oncology
AI Summary: The American Cancer Society launched a new open‑access journal dedicated to pediatric, adolescent and young adult oncology and named its inaugural editor‑in‑chief. The journal aims to centralize research, clinical guidance and policy discussions for younger patients, speeding dissemination of age‑specific evidence and, one hopes, improving outcomes for a frequently overlooked group.
- ACS launches open‑access journal centralizing pediatric and AYA oncology research (7)
- Adolescents and young adults: awareness, survivorship, transition and community (9)
- Global pediatric oncology gatherings spotlight collaboration, training and innovation (14)
- Other pediatric oncology news: research, partnerships, advocacy and care (24)
- All Other Stories